TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03954730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Training
Description: First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Release Technique
Description: Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
Study: NCT03221296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Training (Intervention Group)
Description: Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
Study: NCT03966586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active outreach
Description: Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appointments
Description: Participants in the enhanced-care intervention will be given specific appointment times/dates.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial support
Description: Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microenterprise
Description: YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced counseling
Description: Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical care and counseling
Description: Usual clinical care and counseling
Study: NCT02226016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FG-5000A
Description: a measuring device for the assessment of levator muscle strength
Study: NCT02554643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Nutrition intervention, once a week during 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Nutrition intervention, once a week during 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soccer
Description: Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer
Description: Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Running
Description: Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running
Description: Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
Study: NCT01260805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Drug
Description: Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Drug
Description: Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
Study: NCT02282124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program with monthly sessions
Description: Patients participate in 9 sessions during the first 8th month after transplantaiton
Study: NCT03797326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered orally once a day during each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered orally once a day during each 21-day cycle.
Study: NCT00939172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP607
Description: 3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
Study: NCT04701281

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intra-arterial LIOX + Capecitabine
Description: 5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine
Study: NCT04762355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Placebo-to-match palovarotene ophthalmic solution vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Placebo-to-match palovarotene ophthalmic solution vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Placebo-to-match palovarotene ophthalmic solution vials
Study: NCT00552799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin VK
Description: Biconcave tablet 250mg oral, b.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: biconcave tablet matching active comparator as much as possible in size and shape
Study: NCT02964104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Administered once weekly subcutaneously (s.c., under the skin) for 35 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered once daily subcutaneously for 35 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Administered once daily subcutaneously for 35 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Administered once weekly subcutaneously for 35 days
Study: NCT02519764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration when thirsty.
Description: Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Not hydration when thirsty
Description: Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol.
Study: NCT03199911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antibiotic Product
Description: Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Non-Antibiotic Ointment
Description: Mineral oil/petrolatum-based artificial tear ointment.
Study: NCT02690896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCF Caregiver Support Group
Description: The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Support Groups
Description: Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
Study: NCT02282124

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care, containing one session
Description: Session takes place within the first three months after transplantation
Study: NCT01124786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO-1.01
Description: 1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
Study: NCT04302961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Feedback
Description: Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that does not cause the auditory tool to elicit a noise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Feedback
Description: Participants will complete 8 sessions over a 2-week period of walking gait retraining on a treadmill while receiving no feedback. Participants will be instructed to walk on a treadmill at their desired pace in a manner that they perceive to be their normal walking speed and mechanics.
Study: NCT00500201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB- 773812 60 mg
Description: SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB- 773812 60 mg
Description: SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB- 773812 120 mg
Description: SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB- 773812 120 mg
Description: SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be administered orally by subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be administered orally by subjects.
Study: NCT00177164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable Risperidone (Consta) or oral antipsychotic
Description: Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable Risperidone (Consta) or oral antipsychotic
Description: Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder
Study: NCT04552665

Intervention type: DEVICE
Intervention: KODEX-EPD system
Description: To evaluate the performance of the KODEX-EPD system and collect procedural data and medical images for Philips' internal research and development activities (R\&D)
Study: NCT01080703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
Study: NCT03330990

Intervention type: DRUG
Group type: OTHER
Intervention: Entrectinib
Description: 600 mg oral capsule (fasted and fed)

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam Hydrochloride
Description: 2 mg oral syrup (fasted)
Study: NCT01283503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT02878018

Intervention type: DRUG
Intervention: Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula
Description: Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.

Intervention type: DRUG
Intervention: angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant
Description: prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
Study: NCT01412281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine (AdImmune HA Antigen)
Description: Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine (AdImmune HA Antigen)
Description: Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Virosomal influenza vaccine (CSL HA Antigen)
Description: Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Virosomal influenza vaccine (CSL HA Antigen)
Description: Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
Study: NCT02374710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction: Anterior Tunnel
Description: ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction: Posterior Tunnel
Description: ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
Study: NCT02213705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
Study: NCT02351700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Caldolor
Description: IV Caldolor (IV ibuprofen) intraoperatively and postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV Placebo intraoperatively and postoperatively
Study: NCT02044731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active and Healthy Families
Description: A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
Study: NCT02330939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat- Low glycemic index meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA- Low glycemic index meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFA- Low glycemic index meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat- High glycemic index meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA- High glycemic index meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFA- High glycemic index meal
Study: NCT01174186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
Study: NCT04796480

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: YOGURT
Description: Group 1 was given yogurt

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LACTOSE FREE FORMULA MILK
Description: Group 2 was given lactose free formula milk
Study: NCT02849951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: 12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LT-02 Placebo
Description: 12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
Study: NCT05069480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality-based training equipment.
Description: It is a functional upper extremity rehabilitation device to provide specific therapy with augmented feedback. The equipment facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3D workspace that allows functional therapy exercises in a virtual reality environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: The traditional physical therapy program aimed for inhibition of spasticity, facilitation of muscle action, and improving the motor functions of the involved upper limbs.
Study: NCT01943045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02241551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine/nab-paclitaxel
Description: three cycles of treatment in the gemcitabine/nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: 6 cycles in the mFOLFIRINOX
Study: NCT04755335

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: In this project, The investigators will use Alpinion ECUBE-12R (Alpinion, Bothell, WA) US platform. This state-of-the-art research US machine provides beam formed as well as Plane-Wave imaging options that allow high frame rate imaging. The investigators have characterized the acoustic output of this system for safe human studies and obtained the IRB approval for human studies. It should be noted that our technique is not limited to the Alpinion system; the investigators can also use other US systems, such as Verasonics, Vantage, (Redmond, WA). This technique can be adapted to other modern US machines in the future.